Area of research
Cardiology and Cardiovascular Medicine · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Heart Failure Treatment and Management, Cardiovascular Function and Risk Factors, Atrial Fibrillation Management and Outcomes, and Cardiac Valve Diseases and Treatments.
Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial
Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial
Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction
Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid–Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout
Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty
Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER
Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum
Geographic Differences in Patients with Acute Myocardial Infarction in the PARADISE-MI Trial
THE IMPORTANCE OF BLOOD UREA NITROGEN TO CREATININE RATIO IN PATIENTS WITH HFPEF AND HFREF
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction
Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction
All-cause mortality and location of death in patients with established cardiovascular disease before, during, and after the COVID-19 lockdown: a Danish Nationwide Cohort Study
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction
Importance of diagnostic setting in determining mortality in patients with new-onset heart failure: temporal trends in Denmark from 1997 to 2017
Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: a nationwide study in <scp>Denmark</scp> from 2003–2017
Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality
Time trends in incidence, comorbidity, and mortality of ischemic stroke in Denmark (1996–2016)